Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)

Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Tilsotolimod (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms ILLUMINATE-204
  • Sponsors Aceragen; Idera Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
    • 15 Sep 2020 According to an Idera Pharmaceutical media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, to be held September 19-21, 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top